Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists
- PMID: 20166927
- PMCID: PMC3013229
- DOI: 10.2174/092986710790980050
Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists
Abstract
It is widely accepted that non-endogenous compounds that target CB(1) and/or CB(2) receptors possess therapeutic potential for the clinical management of an ever growing number of disorders. Just a few of these disorders are already treated with Delta(9)-tetrahydrocannabinol or nabilone, both CB(1)/CB(2) receptor agonists, and there is now considerable interest in expanding the clinical applications of such agonists and also in exploiting CB(2)-selective agonists, peripherally restricted CB(1)/CB(2) receptor agonists and CB(1)/CB(2) antagonists and inverse agonists as medicines. Already, numerous cannabinoid receptor ligands have been developed and their interactions with CB(1) and CB(2) receptors well characterized. This review describes what is currently known about the ability of such compounds to bind to, activate, inhibit or block non-CB(1), non- CB(2) G protein-coupled receptors such as GPR55, transmitter gated channels, ion channels and nuclear receptors in an orthosteric or allosteric manner. It begins with a brief description of how each of these ligands interacts with CB(1) and/or CB(2) receptors.
Figures





Similar articles
-
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.Pharmacol Rev. 2010 Dec;62(4):588-631. doi: 10.1124/pr.110.003004. Pharmacol Rev. 2010. PMID: 21079038 Free PMC article. Review.
-
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.J Biol Chem. 2009 Oct 23;284(43):29817-27. doi: 10.1074/jbc.M109.050187. Epub 2009 Sep 1. J Biol Chem. 2009. PMID: 19723626 Free PMC article.
-
Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.J Pharmacol Exp Ther. 2013 Mar;344(3):561-7. doi: 10.1124/jpet.112.201962. Epub 2013 Jan 3. J Pharmacol Exp Ther. 2013. PMID: 23287700 Free PMC article.
-
Cannabinoid receptor antagonists SR141716 and SR144528 exhibit properties of partial agonists in experiments on isolated perfused rat heart.Bull Exp Biol Med. 2005 May;139(5):558-61. doi: 10.1007/s10517-005-0344-9. Bull Exp Biol Med. 2005. PMID: 16224548 English, Russian.
-
Endocannabinoids and Their Pharmacological Actions.Handb Exp Pharmacol. 2015;231:1-37. doi: 10.1007/978-3-319-20825-1_1. Handb Exp Pharmacol. 2015. PMID: 26408156 Review.
Cited by
-
Altered expression of type-1 and type-2 cannabinoid receptors in celiac disease.PLoS One. 2013 Apr 19;8(4):e62078. doi: 10.1371/journal.pone.0062078. Print 2013. PLoS One. 2013. PMID: 23620805 Free PMC article.
-
The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation.Perspect Medicin Chem. 2016 Jun 28;8:17-39. doi: 10.4137/PMC.S32171. eCollection 2016. Perspect Medicin Chem. 2016. PMID: 27398024 Free PMC article.
-
Cerebrovascular Complications Associated with Marijuana Use.Curr Neurol Neurosci Rep. 2021 Apr 7;21(6):25. doi: 10.1007/s11910-021-01113-2. Curr Neurol Neurosci Rep. 2021. PMID: 33825077 Review.
-
Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB1 /CB2 versus GPR55 receptors.Br J Pharmacol. 2020 Apr;177(8):1865-1880. doi: 10.1111/bph.14958. Epub 2020 Feb 11. Br J Pharmacol. 2020. PMID: 31877572 Free PMC article.
-
Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11.Front Psychiatry. 2022 Dec 15;13:1048836. doi: 10.3389/fpsyt.2022.1048836. eCollection 2022. Front Psychiatry. 2022. PMID: 36590635 Free PMC article.
References
-
- Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002;54:161–202. - PubMed
-
- Pertwee RG. Pharmacological actions of cannabinoids. In: Pertwee RG, editor. Cannabinoids. Handbook of Experimental Pharmacology. Vol. 168. Heidelberg: Springer-Verlag; 2005. pp. 1–51. - PubMed
-
- Pertwee RG. Cannabinoids and multiple sclerosis. Mol. Neurobiol. 2007;36:45–59. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases